Traws Pharma, Inc.
TRAW
$2.63
-$0.05-1.87%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.90M | 227.00K | 226.00K | 226.00K | 226.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.90M | 227.00K | 226.00K | 226.00K | 226.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.90M | 227.00K | 226.00K | 226.00K | 226.00K |
| SG&A Expenses | 11.40M | 11.69M | 12.29M | 10.90M | 10.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.17M | 25.13M | 25.14M | 24.32M | 20.87M |
| Operating Income | -20.27M | -24.90M | -24.91M | -24.09M | -20.65M |
| Income Before Tax | -17.82M | -140.05M | -166.52M | -140.79M | -137.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.82 | -140.05 | -166.52 | -140.79 | -137.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.82M | -140.05M | -166.52M | -140.79M | -137.05M |
| EBIT | -20.27M | -24.90M | -24.91M | -24.09M | -20.65M |
| EBITDA | -20.26M | -24.89M | -24.90M | -24.08M | -20.63M |
| EPS Basic | 19.85 | -0.56 | -19.29 | -50.87 | -47.70 |
| Normalized Basic EPS | -9.75 | -13.16 | -18.79 | -15.83 | -13.84 |
| EPS Diluted | 19.77 | -0.64 | -19.30 | -50.88 | -47.71 |
| Normalized Diluted EPS | -9.82 | -13.23 | -18.79 | -15.83 | -13.84 |
| Average Basic Shares Outstanding | 16.83M | 12.02M | 5.90M | 3.66M | 3.53M |
| Average Diluted Shares Outstanding | 17.08M | 12.27M | 5.90M | 3.66M | 3.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |